CRISPR Therapeutics AG [CRSP] stock prices are up 7.78% to $55.15 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CRSP shares have gain 15.18% over the last week, with a monthly amount glided 18.88%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on August 06, 2024, when Needham reiterated its Buy rating and also revised its price target to $84 from $88. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 02, 2024, and set its price target to $90. Wolfe Research started tracking the stock assigning a Peer Perform rating. TD Cowen downgraded its rating to a Underperform but $30 remained the price target by the analyst firm on December 11, 2023. Cantor Fitzgerald downgraded its rating to Neutral for this stock on October 17, 2023. In a note dated September 27, 2023, Mizuho initiated an Buy rating and provided a target price of $82 on this stock.
The stock price of CRISPR Therapeutics AG [CRSP] has been fluctuating between $43.42 and $91.10 over the past year. Currently, Wall Street analysts expect the stock to reach $101.46 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $55.15 at the most recent close of the market. An investor can expect a potential return of 83.97% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -1.65%, Pretax Profit Margin comes in at -1.17%, and Net Profit Margin reading is -1.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.12 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 52.25 points at the first support level, and at 49.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.78, and for the 2nd resistance point, it is at 58.40.
Ratios To Look Out For
It’s worth pointing out that CRISPR Therapeutics AG [NASDAQ:CRSP]’s Current Ratio is 21.64. On the other hand, the Quick Ratio is 21.64, and the Cash Ratio is 2.51. Considering the valuation of this stock, the price to sales ratio is 23.36, the price to book ratio is 2.43.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Nov 11 ’24 when 30000.0 shares were sold. General Counsel and Secretary, KASINGER JAMES R. completed a deal on Oct 14 ’24 to sell 1089.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 4293.0 shares on Oct 14 ’24.
